Skip to main content

Newsweek Acquires Adprime to Expand Its Leadership in Healthcare Media and Advertising

Written by Customer Service on . Posted in Mergers And Acquisitions.

Strategic acquisition strengthens Newsweek’s vertical strategy and adds precision health advertising capabilities across web, mobile, and CTV

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) — Newsweek, the global news and media platform, today announced its acquisition of Adprime, a healthcare-focused advertising platform that enables leading pharmaceutical and healthcare brands to reach both consumers and healthcare professionals through precision-targeted digital campaigns.

This acquisition marks a significant milestone in Newsweek’s long-term strategy to expand its vertical capabilities. By combining Newsweek’s award-winning editorial and research offerings in healthcare with Adprime’s data-driven media products, the company is poised to offer a category-leading solution to healthcare marketers.

“This is part of our thoughtful approach to expand and diversify our business,” said Dev Pragad, Owner and CEO of Newsweek. “We are building a health vertical that spans editorial, rankings, events, subscriptions, and now, advertising. Adprime is a powerful addition that rounds out that offering.”

Adprime offers managed service and programmatic campaign execution, a proprietary healthcare data platform, exclusive endemic content formats, and a curated private exchange. Its clients include pharmaceutical companies, healthcare agencies, and wellness brands. Adprime enables targeting based on professional licensure and user engagement with condition and diagnosis-related content, all while maintaining privacy compliance through anonymized data and selective geographic restrictions. With recent strategic investments in performance CTV, Adprime has significantly expanded its ability to deliver measurable outcomes for healthcare brands.

“Adprime was built to make healthcare marketing more effective and more respectful,” said Rafal Chachura, CTO of Adprime. “Joining Newsweek allows us to scale that vision dramatically while staying true to our mission.”

During the initial integration period, Adprime will continue to operate independently as Adprime by Newsweek, with Rafal Chachura serving as the CTO and Interim Head of Adprime, supported by Newsweek’s dynamic leadership team. Newsweek plans to invest in expanding the platform’s reach, and its roadmap includes deeper integrations across its sales, engineering, and data teams.

“This deal expands our toolkit for health advertisers,” said Danielle Varvaro, Newsweek’s Chief Revenue Officer. “Together with Adprime, we offer a single destination for thought leadership, lead generation, research, rankings, and now, highly targeted media delivery.”

About Adprime:
Adprime is the largest healthcare publisher and ad platform online, as ranked by comScore. It provides unduplicated reach, ensures brand safety, and connects healthcare brands and institutions to their most valuable direct-to-consumer (DTC) and healthcare professional (HCP) audiences. Adprime anticipates the needs of leading healthcare and life sciences companies, continuously evolving its services and growing its value within the dynamic ad tech ecosystem, as further evidenced by its healthcare-specific demand-side platform (DSP).

Adprime creates customized solutions for advertisers, leveraging its expertise, extensive industry reach, advanced targeting, and unparalleled first-party data. For publishers, Adprime is a strategic growth partner that introduces them to brand advertisers most relevant to their content and useful to their highly engaged audiences. For more information, visit Adprime.com.

About Newsweek:
Newsweek is the global digital news organization built around the iconic 93-year-old American magazine. Newsweek reaches 100 million people monthly with its thought-provoking news, opinion, images, graphics, and video delivered across a dozen print and digital platforms. Headquartered in New York City, Newsweek also publishes international editions in EMEA and Asia.

Contact:
Ben Billingsley
Broadsheet Communications for Newsweek
ben@broadsheetcomms.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.